Additional information
| Active substance | Regorafenib |
|---|---|
| Water Retention | Minimal |
| Hepatotoxicity | Yes, can cause elevated liver enzymes and hepatotoxicity |
| Lab Test | Monitoring of liver function and blood counts is recommended |
| Strength | 40mg |
| Also known as | BAY 73-4506 |
| Blood pressure | Can cause hypertension |
| Trade name | Stivarga |
| Storage conditions | Store at room temperature away from moisture and heat |
| Chemical name | 4-(4-((4-(2-(Methylcarbamoyl)pyridin-4-yl)oxy)phenylamino)phthalazin-1-yl)-3-fluorobenzenesulfonamide |
| Formula | C21H15ClF4N4O3 |
| Substance class | Kinase inhibitor |
| Main action | Targets and inhibits tumor angiogenesis, oncogenesis, and the tumor microenvironment |
| Half-life | Approximately 28 hours |
| Dosage (medical) | Typically 160 mg taken orally once daily for the first 3 weeks of a 4-week cycle |
| Dosage (sports) | Not applicable as it is not used for sports enhancement |
| Effects | Inhibits tumor growth and reduces tumor vascularization |
| Side effects | Hand-foot skin reactions, diarrhea, fatigue, hypertension, rash, decreased appetite, and infection |
| Use in sports | None, as it is not an enhancing drug |
| Manufacturer | Natco Pharmaceuticals Ltd. |
| Packing | 28 tabs/bottle |
Tavanic 500 mg Sanofi
Prograf 1mg Astellas Pharma
Prograf 5mg Astellas Pharma
Januvia 100mg Merckgroup
FUCIDIN 500 mg Abdi Ibragim
Rovamycine 3.000.000 iu Eczacibasi
Norvacs 10 mg Pfizer 


Reviews
There are no reviews yet.